Moderna, Inc. MRNA
Verdict: Sell. Fair value $50.80 against a price of $32.17 on 6 Jan 2026, 58% above the price.
In plain words
The case for: Narrow competitive moat provides durability. Industry tailwinds with growing market.
The case against: Competitive moat at risk of erosion. Intense competitive pressure could compress margins. Revenue plummeted from $18.88B in 2022 to $3.20B in 2024. Net Income swung from a profit of $8.36B....
Main risks
- Revenue & Profit Collapse: Revenue has plummeted from a peak of $18.88B in 2022 to $2.2B TTM, while swinging from over $12B in net income to significant annual losses, indicating a severe post-pandemic business model challenge.
- Aggressive Cash Burn: The company is experiencing substantial negative free cash flow ($-2.66B TTM), eroding the cash reserves built during its peak years and raising concerns about long-term sustainability without a new blockbuster product.
- Value-Destructive Capital Allocation: The 3-year ROIIC is extremely negative, indicating that capital invested over the past three years has coincided with a catastrophic decline in operating profits, questioning the effectiveness of its reinvestment strategy.
- Revenue plummeted from $18.88B in 2022 to $3.20B in 2024. Net Income swung from a profit of $8.36B...
- Operating Cash Flow has turned sharply negative, from +$4.98B in 2022 to -$3.00B in 2024. The...
- Intense competitive environment